{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:23:16Z","timestamp":1770330196151,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00277-022-05037-w","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T20:23:06Z","timestamp":1668198186000},"page":"243-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma"],"prefix":"10.1007","volume":"102","author":[{"given":"Yosuke","family":"Masamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arika","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Maki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"issue":"4","key":"5037_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","volume":"34","author":"JR Cerhan","year":"2020","unstructured":"Cerhan JR (2020) Epidemiology of follicular lymphoma. Hematol Oncol Clin North Am 34(4):631\u2013646. https:\/\/doi.org\/10.1016\/j.hoc.2020.02.001","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9873","key":"5037_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/s0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210. https:\/\/doi.org\/10.1016\/s0140-6736(12)61763-2","journal-title":"The Lancet"},{"issue":"14","key":"5037_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trneny M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331\u20131344. https:\/\/doi.org\/10.1056\/NEJMoa1614598","journal-title":"N Engl J Med"},{"issue":"23","key":"5037_CR4","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1002\/cncr.28350","volume":"119","author":"P Martin","year":"2013","unstructured":"Martin P, Byrtek M, Dawson K, Ziemiecki R, Friedberg JW, Cerhan JR, Flowers CR, Link BK (2013) Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Cancer 119(23):4129\u20134136. https:\/\/doi.org\/10.1002\/cncr.28350","journal-title":"Cancer"},{"issue":"3","key":"5037_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/hon.2614","volume":"37","author":"T Konishi","year":"2019","unstructured":"Konishi T, Kanemasa Y, Sasaki Y, Okuya T, Yamaguchi T, Funasaka C, Shimoyama T, Omuro Y (2019) Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma. Hematol Oncol 37(3):303\u2013307. https:\/\/doi.org\/10.1002\/hon.2614","journal-title":"Hematol Oncol"},{"issue":"3","key":"5037_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00277-021-04576-y","volume":"101","author":"Y Masamoto","year":"2022","unstructured":"Masamoto Y, Shimura A, Kurokawa M (2022) Reduced bendamustine for elderly patients with follicular lymphoma. Ann Hematol 101(3):713\u2013715. https:\/\/doi.org\/10.1007\/s00277-021-04576-y","journal-title":"Ann Hematol"},{"key":"5037_CR7","doi-asserted-by":"publisher","unstructured":"Masamoto Y, Taoka K, Maki H, Kurokawa M (2022) Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab. Ann Hematol 101(12):2795\u20132797.\u00a0https:\/\/doi.org\/10.1007\/s00277-022-04987-5","DOI":"10.1007\/s00277-022-04987-5"},{"issue":"11","key":"5037_CR8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/blood.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J, Hoster E, Hochster HS, Hiddemann W, Marcus R, Kimby E, Herold M, Sebban C, Gyan E, Foon K, Nielsen T, Vitolo U, Salles GA, Shi Q, Flowers CR (2022) Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood 139(11):1684\u20131693. https:\/\/doi.org\/10.1182\/blood.2020010263","journal-title":"Blood"},{"issue":"6","key":"5037_CR9","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/bloodadvances.2020002724","volume":"5","author":"C Casulo","year":"2021","unstructured":"Casulo C, Dixon JG, Ou FS, Hoster E, Peterson BA, Hochster HS, Brice P, Ladetto M, Hiddemann W, Marcus R, Kimby E, Herold M, Nielsen T, Morschhauser F, Rummel M, Hagenbeek A, Vitolo U, Salles GA, Shi Q, Flowers CR (2021) Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Adv 5(6):1737\u20131745. https:\/\/doi.org\/10.1182\/bloodadvances.2020002724","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05037-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-05037-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-05037-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T03:04:43Z","timestamp":1672715083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-05037-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5037"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-05037-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants followed the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Yosuke Masamoto received lecture fees from SymBio Pharmaceutical, Nippon Shinyaku, Eisai, and Chugai Pharmaceutical. Akira Honda received lecture fees from Nippon Shinyaku and Chugai Pharmaceutical. Mineo Kurokawa received research funding from Chugai Pharmaceutical, Eisai, and Nippon Shinyaku. Mineo Kurokawa received the advisory fee from Chugai Pharmaceutical. Mineo Kurokawa received the lecture fee from Eisai, Chugai Pharmaceutical, and Nippon Shinyaku.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}